摘要
目的探讨SialylLewis-X(SLeX)抗原在大肠癌肝转移中的作用及临床意义。方法采用大肠癌Lovo、HT29细胞与人脐静脉血管内皮及内皮细胞的粘附试验,分别用扫描电镜及透射电镜观察Lovo、HT29细胞与脐静脉血管内皮及内皮细胞的粘附性及SLeX单抗封闭大肠癌细胞后,这种粘附性的改变;采用实验性裸鼠大肠癌肝转移模型分别观察SLeX单抗封闭Lovo、HT29细胞前后对实验性裸鼠大肠癌肝转移的影响。结果高表达SLeX抗原的Lovo细胞与脐静脉血管内皮的粘附性较低表达SLeX抗原的HT29细胞强,Lovo细胞与脐静脉血管内皮细胞的连接方式与HT29细胞明显不同;高表达SLeX抗原的Lovo细胞引起裸鼠肝转移率高于低表达SLeX抗原的HT29细胞。结论大肠癌细胞表面SLeX抗原在大肠癌细胞与脐静脉血管内皮细胞的粘附及实验性裸鼠肝转移中起重要作用,SLeX单抗能有效地抑制肿瘤细胞与脐静脉血管内皮细胞的粘附,并能降低实验性裸鼠肝转移的形成。
Objective：To investigate the clinical significance of Sialyl Lewis-X （SLeX） antigen in liver metastases of human colon carcinoma. Methods：Observing the adhesive potential of Lovo and HT29 cell to human umbilical vein endothelium and endothelial cell and alteration of the adhesive potential after colon carcinoma cells were sealed by SLeX monoclonal antibody by means of the adhesive test in which a scanning electronic microscope and a transmission electronic microscope were used; observing the effects of SLeX monoclonal antibody on hepatic metastases of colon carcinoma in the experimental nude mice before and after the Lovo and HT29 cells were sealed by SLeX monoclonal antibody. Results：Lovo cells with high expressive SLeX antigen contained more powerful adhesive potential to umbilical vein endothelium titan that of HT29 cells to low metastases potential. The link between Lovo cells and umbihcal vein endothelial cells was significantly different from that between HT29 cells and umbilical vein endothelial cells. The Lovo cells with the high expression of SLeX antigen showed a higher hepatic metastases rate in nude mice than HT29 cells with low expression of SLeX antigen. Conclusion：The colon carcinoma cell surface SLeX antigen played an important role both in adhesion between colon carcinoma cells and umbilical vein endothelial cells and in hepatic metastases in experimental nude mice. The SLeX monoclonal antibody could restrain adhesion between tumor cells and vein endothelial cells and reduce hepatic metastases formation in experimental nude mice.
出处
《临床肿瘤学杂志》
CAS
2006年第4期269-273,共5页
Chinese Clinical Oncology
